株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

がん治療用モノクローナル抗体の世界市場 - 成長、動向、予測(2019年~2024年)

Cancer Monoclonal Antibodies Market - Growth, Trends, and Forecast (2019 - 2024)

発行 Mordor Intelligence LLP 商品コード 353907
出版日 ページ情報 英文 115 Pages
納期: 2-3営業日
価格
本日の銀行送金レート: 1USD=109.81円で換算しております。
Back to Top
がん治療用モノクローナル抗体の世界市場 - 成長、動向、予測(2019年~2024年) Cancer Monoclonal Antibodies Market - Growth, Trends, and Forecast (2019 - 2024)
出版日: 2019年04月01日 ページ情報: 英文 115 Pages
概要

世界のがん治療用モノクローナル抗体市場は、2019年から2024年にかけて8.7%のCAGRで推移することが予測されています。がんの罹患率の上昇、ゲノム研究への投資増加、技術進歩、癌細胞を標的とするモノクローナル抗体の特異性などが当市場の主な成長要因となっています。

当レポートでは、世界のがん治療用モノクローナル抗体市場を調査し、市場の概要、タイプ・治療薬・用途・地域別の市場規模の推移と予測、市場の成長要因および阻害要因の分析、市場機会、競合情勢、主要企業のプロファイルなど、包括的な情報を提供しています。

目次

第1章 イントロダクション

  • 調査成果
  • 調査の前提条件
  • 調査範囲

第2章 調査方法

第3章 エグゼクティブサマリー

第4章 市場のダイナミクス

  • 市場概況
  • 市場成長要因
    • がんの罹患率の増加
    • ゲノム研究および開発への投資増加
    • がん細胞を標的とするモノクローナル抗体の技術発展と関心の高まり
  • 市場の阻害要因
    • 厳格な規制ガイドライン
    • 臨床試験の失敗の増加による研究開発の長期化
  • ファイブフォース分析
    • 買い手の交渉力
    • 供給企業の交渉力
    • 新規参入業者の脅威
    • 代替品の脅威
    • 競争企業間の敵対関係

第5章 市場セグメンテーション

  • タイプ別
    • マウス抗体
    • キメラ抗体
    • ヒト化抗体
  • 治療薬別
    • ベバシズマブ(アバスチン)
    • リツキシマブ(リツキサン)
    • トラスツズマブ(ハーセプチン)
    • セツキシマブ(エルビタックス)
    • パニツムマブ(ベクティビックス)
    • その他
  • 用途別
    • 乳がん
    • 血液がん
    • 肝臓がん
    • 脳腫瘍
    • 大腸がん
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Amgen Inc
    • Bristol Myers Squibb Company
    • Eli Lilly and Company
    • F. Hoffmann-La Roche AG
    • Genmab A/S
    • GlaxoSmithKline plc
    • Johnson & Johnson
    • Novartis AG
    • Seattle Genetics Inc
    • Spectrum Pharmaceuticals Inc

第7章 市場機会および将来動向

目次
Product Code: 52784

Market Overview

Global Cancer Monoclonal Antibodies market is expected to witness a CAGR of 8.7% during the forecast period. Certain factors that are driving the market growth include growing prevalence of cancer, increasing investment in research and development of genomic studies, rising advancements and preference towards the specificity of monoclonal antibodies to target cancer.

Cancer is one of the leading causes of death globally. There were 10.9 million new cases, in 2002, which increased to 14.1 million, in 2012 (approximately 30% growth in a decade). The WHO expects this number to increase by 70%, over the next two decades. According to the WHO, almost 70% of deaths occur in low and middle-income countries. The increment in data is expected to provide the basis for any national policy on cancer, leading to an increase in the percentage of people choosing cancer treatment. In the healthcare sector, cancer is one of the biggest concerns. Thus, the increased use of monoclonal antibodies for the treatment of cancer is driving this market.

However, following the regulatory guidelines for monoclonal antibodies related to cancer is a highly rigorous process in most of the regions, globally. The guidelines provide a comprehensive description of the manufacturing processes including quality, good manufacturing practices, process validation, the potential for degradation, and the need for stability studies. A stringent regulatory scenario exists globally, such as the US FDA, the European Medicines Agency (EMA), and the Korean FDA. Similar to biologics, biosimilar also faces similar restrictions for getting the approval of monoclonal antibodies in the market. Since it is a time-consuming process, it is considered as one of the major hindering factors for this market. Other factors that restrain the growth of the global cancer monoclonal antibodies market are the long duration of research and development before clinical trials and the rise in the failures of mAbs in clinical trials.

Scope of the Report

Monoclonal antibodies are highly specific to cancer cells as they bind to the proteins on their surface and stimulate an immune response. This market consists of several types of monoclonal antibodies and much more in the pipeline.

Key Market Trends

Trastuzumab (Herceptin) is Expected to Hold Significant Market Share in Monoclonal Antibody Therapies

Trastuzumab (Herceptin) is a monoclonal antibody used to treat breast cancer. It is also an approved first-line treatment for HER2+ metastatic cancer of the stomach or gastro-oesophageal junction. According to Roche's (manufacturer of the drug) annual report, in 2015, the annual sales revenue generated from the drug was CHF 6,538 million (10% higher than 2014). A major contributor to this growth was the increased access to the drug, in China. The United States has also played a vital role in this growth, as sales revenue generated from the drug increased by 15% and increased further by 4%, in 2016. The country witnessed continued growth, mainly, due to the longer duration of treatment in combination with Perjeta.

However, the common side-effects (fever, infection, cough, rash, and others) and severe side-effects (heart failure, allergic reaction, and lung disorders) are associated with the drug. The drug may also result in unnecessary issues for the baby if taken during pregnancy. These side-effects may affect the adoption rate and, hence, can act as an inhibiting factor.

North America Dominates the Market and Expected to do Same in the Forecasted Period

The market is growing at a strong pace in North America. The pharmaceutical and biotechnology firms have gained abundant knowledge and expertise in cancer monoclonal antibodies. With the approval of murine cancer monoclonal antibodies, followed by chimeric and fully human cancer monoclonal antibodies, the sales and the rate of product approvals have increased over the past few years. Furthermore, depending on the high percentage of molecules that are in the pipeline, this scenario can change. Human monoclonal antibodies (mAbs) is the fastest-growing category of mAb therapeutics entering the clinical study. Furthermore, with the trend towards developing targeted therapeutics, the focus on fully humanized cancer monoclonal antibodies is expected to increase, owing to perceived low-level of immunogenicity of these agents. The first human mAb was approved by the United States FDA, in 2002. Since then, many human mAbs have received FDA approval and few are in the phase-3 studies. Sales of Rituxan (rituximab) grew by 5% in 2015, propelled by the strong demand in the country. Moreover, it is the single largest market for the oncology product, Avastin, accounts for approximately 47% of its global sales. Herceptin, a competitor for Avastin and Rituxan, recorded a 15% sales increase in 2015, with sales of around USD 6.59 billion.

Competitive Landscape

The global Cancer Monoclonal Antibodies market is highly competitive and consists of a number of major players. Companies like Amgen Inc, Bristol Myers Squibb Company, Eli Lilly and Company, F. Hoffmann-La Roche AG, Genmab A/S, GlaxoSmithKline plc, Johnson & Johnson, Novartis AG, Seattle Genetics Inc, Spectrum Pharmaceuticals Inc., among others, hold the substantial market share in the Cancer Monoclonal Antibodies market.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Deliverables
  • 1.2 Study Assumptions
  • 1.3 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Growing Prevalence of Cancer
    • 4.2.2 Increasing Investment in Research and Development of Genomic Studies
    • 4.2.3 Rising Advancements and Preference Towards Specificity of Monoclonal Antibodies to Target Cancer
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Guidelines
    • 4.3.2 Long Duration of Research and Development with Rising Failures in Clinical Trials
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 Types of Monoclonal Antibody
    • 5.1.1 Murine Antibodies
    • 5.1.2 Chimeric Antibodies
    • 5.1.3 Humanized Antibodies
  • 5.2 Monoclonal Antibody Therapies
    • 5.2.1 Bevacizumab (Avastin)
    • 5.2.2 Rituximab (Rituxan)
    • 5.2.3 Trastuzumab (Herceptin)
    • 5.2.4 Cetuximab (Erbitux)
    • 5.2.5 Panitumumab (Vectibix)
    • 5.2.6 Others
  • 5.3 Application
    • 5.3.1 Breast Cancer
    • 5.3.2 Blood Cancer
    • 5.3.3 Liver Cancer
    • 5.3.4 Brain Cancer
    • 5.3.5 Colorectal Cancer
    • 5.3.6 Others
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 US
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 UK
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Amgen Inc
    • 6.1.2 Bristol Myers Squibb Company
    • 6.1.3 Eli Lilly and Company
    • 6.1.4 F. Hoffmann-La Roche AG
    • 6.1.5 Genmab A/S
    • 6.1.6 GlaxoSmithKline plc
    • 6.1.7 Johnson & Johnson
    • 6.1.8 Novartis AG
    • 6.1.9 Seattle Genetics Inc
    • 6.1.10 Spectrum Pharmaceuticals Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Back to Top